Sanofi (NASDAQ:SNY) is one of the The best low-volatility, large-cap stocks to invest in.. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a price target of €110.
On the same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate to severe chronic spontaneous urticaria (CSU) in adult and adolescent patients aged 12 years and older with an inadequate response to histamine-1 (H1AH) antihistamines and who have not previously received anti-immunoglobulin E (IgE) therapy for CSU.”
Management reported that Sanofi and Regeneron’s Dupixent can be used as a first-line targeted treatment option and gained approval as the first targeted drug in the EU in more than a decade for chronic spontaneous urticaria.
Sanofi (NASDAQ:SNY) added that the approval was based on Phase 3 studies that demonstrated a significant reduction in itching and hives at 24 weeks compared to placebo due to Dupixent.
Sanofi (NASDAQ:SNY) researches, produces and distributes pharmaceutical products. The company’s operations are divided into pharmaceuticals, consumer healthcare and vaccines segments.
While we recognize SNY’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.